avid Meerman Scott`s book The New Rules of Marketing and PR opened people`s eyes to the new realities of marketing and public relations on the Web. Six months on the BusinessWeek bestseller list and published in 26 languages from Bulgarian to Vietnamese, New Rules, now in its second edition, is a modern business classic. Scott`s popular blog and hundreds of speaking engagements around the world give him a singular perspective on how businesses are implementing new strategies to reach buyers. His newest book Real-Time Marketing and PR: How to Instantly Engage Your Market, Connect with Customers, and Create Products that Grow Your Business Now was released in November 2010. It achieved #2 on the Wall Street Journal bestseller list and #3 on the USA Today bestseller list. He is also the co-author (with Brian Halligan) of the hit book Marketing Lessons from the Grateful Dead: What Every Business Can Learn from the Most Iconic Band in History and wrote three other books including World Wide Rave. His blog - Web Ink Now - is ranked by AdAge Power 150 as a top worldwide marketing blog. He is a recovering VP of marketing for two publicly traded technology companies and was also Asia marketing director for Knight-Ridder, at the time one of the world`s largest newspaper and electronic information companies. David has lived and worked in New York, Tokyo, and Hong Kong. He currently lives in the Boston area and writes for Huffington Post. www.speakinc.com Book David Scott as akeynote ...

NOT WORKING ANYMORE 24/03/2012 DONT FORGET TO MAKE BACKUPS *New Update Available* ra1n0fpa1n.freeforums.org Please Sign up Older Version Method 1 (USB Mode) -Download ghost commander in the android market -Connect your usb or download just the hacked application.js here and copy it to a location where you can find it In (Removeable disk) and then disconnect usb Hacked Tiny Tower 06/02/2012 Includes Bux and Coins www.mediafire.com -Open ghost commander you need to find the actual application.js sdcard\.ngmoco\add56081aa449341e27b06b120a6dab4 - if you cant find .ngmoco you just need to find a folder called add56081aa449341e27b06b120a6dab when you find it add it to your favorites then open your favorites hold it down and click edit copy its location then look for the Hacked application.js and copy the new application.js in place Method 2 (Download Via Phone) -Download ghost commander in the android market -download just the application.js through your phone here www.mediafire.com -Open ghost commander you need to find the actual application.js sdcard\.ngmoco\add56081aa449341e27b06b120a6dab4 - if you cant find .ngmoco you just need to find a folder called add56081aa449341e27b06b120a6dab when you find it add it to your favorites then open your favorites hold it down and click edit copy its location then look for the Hacked application.js should be in your downloads folder and copy the Hacked application.js in place Dont Forget To Comment Rate And Subcribe This will be my final ...

Chief Scientific Officer (CSO) for OmniBio Dr. Charles Dinarello discusses Alpha-1 Antitrypsin (AAT) research and it's potential as a therapy for Type 1 diabetes. He is also a Professor of Medicine and Immunology at the University of Colorado Denver who has published over 700 original research articles on cytokines, particularly interleukin‐1 (IL‐1) and tumor necrosis factor, and is considered a "founding father" of cytokine biology. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

Dr. Charles Dinarello, Chief Scientific Officer of OmniBio, is a co-author of an article that is now available in the journal Blood, which is the premier journal of the American Society of Hematology. The paper describes the use of Alpha 1 antitrypsin (AAT) to treat mice with a lethal form of rejection of bone marrow transplantation. Mice survive the crisis with AAT treatment. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

OmniBio CEO Dr. James Crapo talks about the important research taking place with Alpha-1 Antitrypsin (AAT). This safe and powerful molecule is being used in trials for type 1 diabetes and Graph vs. Host disease (GVH). OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com